Pegaptanib
Drug Info:
Top
Pegaptanib
Brand names: Macugen®
- Drug Forms:
- Pegaptanib Sodium Solution for injection (below)
- Pegaptanib intravitreal injection
Pegaptanib Sodium Solution for injection
What is this medicine?
PEGAPTANIB (peg AP ta nib) is a drug that is injected into the eye. It is used to treat macular degeneration. This treatment results in a slowing of the disease and helps to maintain vision. It is not a cure.
This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.
What should I tell my health care provider before I take this medicine?
They need to know if you have any of these conditions:
•cataracts or glaucoma
•eye infection
•an unusual or allergic reaction to Pegaptanib, other medicines, foods, dyes, or preservatives
•pregnant or trying to get pregnant
•breast-feeding
How should I use this medicine?
This medicine is injected into the eye by an eye doctor who specializes in this treatment. The eye doctor will numb your eye and give you antibiotic eye drops. The injection is usually given every 6 weeks.
Talk to your pediatrician regarding the use of this medicine in children. Special care may be needed.
Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.
NOTE: This medicine is only for you. Do not share this medicine with others.
What if I miss a dose?
This does not apply.What may interact with this medicine?
Interactions are not expected.
Do not use any other eye products without asking your doctor or health care professional.
This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.
What should I watch for while using this medicine?
Your eye doctor will monitor the effects of this medicine closely. You may need to return to the office between 2 and 7 days after the treatment for a check on your condition and your response to the treatment.
What side effects may I notice from receiving this medicine?
Side effects that you should report to your doctor or health care professional as soon as possible:
•allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue
•changes in vision
•eye pain
•sensitivity of the eyes to light
•severe headache
•swelling or redness of the eye or eyelid
Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are or are bothersome):
•temporary blurred vision or eye irritation
•dizziness
•headache
This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Where should I keep my medicine?
This drug is given in a hospital or clinic and will not be stored at home.
Last updated: 1/3/2005 1:01:00 PM
Important Disclaimer: The drug information provided here is for educational purposes only. It is intended to supplement, not substitute for, the diagnosis, treatment and advice of a medical professional. This drug information does not cover all possible uses, precautions, side effects and interactions. It should not be construed to indicate that this or any drug is safe for you. Consult your medical professional for guidance before using any prescription or over the counter drugs.
Related Videos:
Top
Pegaptanib
Wikipedia on Answers.com:
Top
Pegaptanib
 |
This article does not cite any references or sources. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (December 2009) |
| Clinical data | |
|---|---|
| Trade names | Macugen |
| AHFS/Drugs.com | monograph |
| MedlinePlus | a607057 |
| Pregnancy cat. | B(US) |
| Legal status | ℞-only (US) |
| Routes | Intravitreal |
| Pharmacokinetic data | |
| Half-life | 10 days |
| Identifiers | |
| CAS number | 222716-86-1  |
| ATC code | S01LA03 |
| PubChem | CID 24847876 |
| DrugBank | DB04895 |
| UNII | 2H1PA8H1EN |
| ChEMBL | CHEMBL1201704  |
| Chemical data | |
| Formula | C294H342F13N107Na28O188P28 |
| Mol. mass | 50 kilodaltons |
 (what is this?) (verify) |
|
Pegaptanib sodium injection (brand name Macugen) is an anti-angiogenic medicine for the treatment of neovascular (wet) age-related macular degeneration (AMD). It was discovered by Gilead Sciences and licensed in 2000 to EyeTech Pharmaceuticals, now OSI Pharmaceuticals, for late stage development and marketing in the United States. Outside the U.S.A. Macugen is marketed by Pfizer. Approval was granted by the U.S. Food and Drug Administration (FDA) in December 2004.
Pegaptanib is a pegylated anti-VEGF aptamer, a single strand of nucleic acid that binds with specificity to a particular target. Pegaptanib specifically binds to VEGF 165, a protein that plays a critical role in angiogenesis (the formation of new blood vessels) and increased permeability (leakage from blood vessels), two of the primary pathological processes responsible for the vision loss associated with neovascular AMD.
Pegaptanib is administered in a 0.3 mg dose once every six weeks by intravitreal injection.
|
||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
